38 results
Risk factor for VTE in cancer patients

Tumor type 

• Very high risk: gastric, pancreas, brain 

•
Risk factor for ... • Very high risk ... brain • High risk ... : lung, hematologic ... #VTE #cancer #oncology
Pulmonary Embolism Treatment
Systemic Thrombolysis
 - Exclude contraindications.
 - Indications:
   - Massive PE (definite indication)
submassive PE (risk ... 50mg IV) - 2% risk ... of ICH and 6% risk ... who are higher risk ... AcutePE #Management #CriticalCare
Pulmonary Embolism - Risk Stratification and Prognostication based on scores and clinical features

 • Bova score
Pulmonary Embolism ... - Risk Stratification ... @nickmmark #Pulmonary ... #Embolism #Risk ... stratification #criticalcare
COVID-19: ICU Guidelines for the Non-Intensivist
Infection Control
Risk Factors for Severe Disease
Initial Laboratory Workup
COVID-19 Specific Medications
Respiratory
Cardiac
Hematologic
Neuro/Sedation

#COVID19 #ICU
Infection Control Risk ... Respiratory Cardiac Hematologic ... #COVID19 #ICU #criticalcare
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
diagnosis and risk-stratification ... • Risks: infection ... Management #treatment #hematology ... #oncology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Patient risk stratification ... thrombosis; PE = pulmonary ... Anticoagulation #Management #Hematology ... #Oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
patients at high risk ... interactions and bleeding risk ... also balance the risk ... Anticoagulation #Management #Hematology ... #Oncology
Rheumatoid Arthritis Summary
MCP and PIP Involvement, Spares DIP, Carpal Tunnel, Sicca Syndrome, Epi/Scleritis, Heart Disease, Rheumatoid
Rheumatoid Nodules, Pulmonary ... splenomegaly), Increased Risk ... RA #diagnosis #rheumatology
Tranexamic Acid - Indications and Pharmacology
Pharmacokinetics:
 • MOA: Inhibits plasminogen activation to plasmin & inhibits fibrinolysis
Indications and Pharmacology ... fatigue; Increases risk ... #Indications #Pharmacology ... #hematology
Monoclonal Gammopathy of Undetermined Significance (MGUS) - Summary Framework

Hematologic disorder characterized by the presence of either
greatest future risk ... hepatosplenomegaly • 1.5% risk ... lesions (CRAB) • 1% risk ... 500 mg/24 h • Risk ... #diagnosis #oncology